Nuclear Factor Erythroid 2 Related Factor 2 (Nrf2) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) | |
|---|---|
| Gene | NFE2L2 |
| UniProt ID | Q16236 |
| PDB Structure IDs | 2FLU, 3ZGC, 4UDD |
| Molecular Weight | 60,300 Da (full-length) |
| Subcellular Localization | Cytoplasm (sequestered by KEAP1); nucleus (active) |
| Protein Family | CNC-bZIP family (Nrf1, Nrf2, Nrf3, Bach1, Bach2) |
NRF2 is the master regulator of antioxidant response and cellular defense. It coordinates expression of over 200 genes involved in oxidative stress protection, metabolism, and detoxification.
Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) is a CNC-bZIP family (Nrf1, Nrf2, Nrf3, Bach1, Bach2) member.
NRF2 contains a Neh (Nrf2-ECH) domain structure with 7 conserved regions. Under basal conditions, NRF2 binds KEAP1 (Kelch-like ECH-associated protein 1) in the cytoplasm, which targets NRF2 for ubiquitination and proteasomal degradation. Upon oxidative stress, cysteine residues on KEAP1 are oxidized, releasing NRF2. NRF2 translocates to the nucleus, heterodimerizes with small Maf proteins, and binds the Antioxidant Response Element (ARE) to activate target genes.
NRF2 activity declines with age and in neurodegenerative diseases. In AD, Aβ and tau pathology impairs NRF2 signaling. In PD, oxidative stress from dopamine metabolism overwhelms NRF2 protection. In ALS, motor neurons show reduced NRF2 expression. Enhancing NRF2 is a major therapeutic strategy.
NRF2 activators include: (1) Covalent KEAP1 inhibitors (bardoxolone methyl, sulforaphane), (2) Non-covalent disrupters, (3) NRF2 stabilizers (e.g., Oltipraz), (4) Gene therapy (AAV-NRF2). Clinical trials ongoing for bardoxolone methyl in AD.
ATF4 is widely expressed in the central nervous system, with high levels in the hippocampus, cortex, and hypothalamus. It is induced by cellular stress including oxidative stress, amino acid deprivation, and endoplasmic reticulum stress.
In Alzheimer's disease, ATF4 dysregulation contributes to synaptic plasticity impairment and memory deficits. In Parkinson's disease, ATF4 is involved in the cellular response to dopaminergic neuron stress. In ALS, ATF4 regulates the expression of genes involved in motor neuron survival.
Targeting ATF4 expression or activity represents a potential therapeutic approach for neurodegenerative diseases. Small molecule activators of ATF4 may provide neuroprotective effects.
ATF4 knockout mice show deficits in long-term memory and synaptic plasticity. Transgenic mice overexpressing ATF4 have been used to study its role in neurodegeneration.
Future research should focus on understanding the cell-type specific functions of ATF4 and developing ATF4-targeted therapeutics.
The study of Nuclear Factor Erythroid 2 Related Factor 2 (Nrf2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] https://pubmed.ncbi.nlm.nih.gov/14583151/
[2] https://pubmed.ncbi.nlm.nih.gov/15660156/
[3] https://pubmed.ncbi.nlm.nih.gov/18669862/
[4] https://pubmed.ncbi.nlm.nih.gov/21471211/
[5] https://pubmed.ncbi.nlm.nih.gov/24711158/
[6] https://pubmed.ncbi.nlm.nih.gov/26431658/
[7] https://pubmed.ncbi.nlm.nih.gov/28992421/
[8] https://pubmed.ncbi.nlm.nih.gov/31222207/
ATF4 is widely expressed in the central nervous system, with high levels in the hippocampus, cortex, and hypothalamus. It is induced by cellular stress including oxidative stress, amino acid deprivation, and endoplasmic reticulum stress.
In Alzheimer's disease, ATF4 dysregulation contributes to synaptic plasticity impairment and memory deficits. In Parkinson's disease, ATF4 is involved in the cellular response to dopaminergic neuron stress. In ALS, ATF4 regulates the expression of genes involved in motor neuron survival.
Targeting ATF4 expression or activity represents a potential therapeutic approach for neurodegenerative diseases. Small molecule activators of ATF4 may provide neuroprotective effects.
ATF4 knockout mice show deficits in long-term memory and synaptic plasticity. Transgenic mice overexpressing ATF4 have been used to study its role in neurodegeneration.
Future research should focus on understanding the cell-type specific functions of ATF4 and developing ATF4-targeted therapeutics.